Eli Lilly announced on September 24, 2026 that Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin, has been approved by the Food and Drug Administration for adults with type 2 diabetes. The agency’s 2026 novel-approvals table carries the approval date as September 23. The decision rests on four phase three QWINT trials that together enrolled more than 3,400 adults.
For a patient who injects a long-acting insulin every day, the arithmetic is stark: 52 injections a year instead of 365. The label is narrower than that sounds, though, and it draws lines around who can use the drug and what it replaces.
The approved population and the one injection it replaces
According to Lilly’s approval release, Onswik is indicated, along with diet and exercise, to control high blood sugar in adults with type 2 diabetes. The wording covers adults only, and it excludes type 1 diabetes, a group the release says should not use the drug. The listing in the FDA’s table of 2026 novel approvals confirms the drug name, the active ingredient and the September 23 date.
What the weekly shot replaces is the basal injection, the background insulin taken once a day to hold glucose steady between meals. Mealtime insulin is a separate question that the approval does not settle. The label describes injection on the same day each week, not into a vein or muscle and not through an insulin pump. If a dose is missed, it can be taken as soon as possible within 4 days, or 96 hours, after the scheduled time; past that point the dose is skipped.
Four QWINT trials and what non-inferior means
Each of the four QWINT studies compared weekly Onswik with a daily basal insulin, and each met its primary endpoint of non-inferior A1C reduction from baseline. QWINT-1 enrolled 795 adults who had not used insulin before and compared Onswik with insulin glargine U-100, with the primary objective at week 52. QWINT-2 enrolled 928 insulin-naive adults against insulin degludec U-100, also at week 52. QWINT-3 enrolled 986 adults already on basal insulin, against degludec U-100, with the primary objective at week 26 and treatment running 78 weeks. QWINT-4 enrolled 730 adults on basal plus mealtime insulin, against glargine U-100, with the primary objective at week 26. The four enrollments sum to 3,439.
Non-inferior is a specific statistical claim: the weekly insulin lowered A1C by an amount comparable to the daily comparator, within a pre-set margin. It does not mean better. The release prints no numeric A1C differences, and readers wanting the figures can turn to the peer-reviewed reports, including the New England Journal of Medicine paper on efsitora versus degludec in people without previous insulin treatment and the Lancet report of QWINT-4, the trial in adults treated with both basal and prandial insulin.
That last design matters for the claim that a weekly shot replaces a daily one. In QWINT-4 the participants kept their mealtime insulin; only the basal component changed from daily to weekly. So the evidence supports swapping one injection type for another, not retiring injections altogether, and the trial programme spans people new to insulin as well as people already on basal or basal-plus-mealtime regimens.
Type 1 diabetes and the hypoglycemia warning
The release states that Onswik should not be used by people who have type 1 diabetes because of an increased risk of severe hypoglycemia. That is the label’s sharpest boundary. Low blood sugar is listed as a serious risk that can be fatal, with symptoms that include dizziness, confusion, shakiness and sweating, and the drug is not to be taken during an episode of low blood sugar.
The release says patients should discuss with a health care provider how to manage low blood sugar before starting treatment. Side effects can be reported to the FDA’s MedWatch program.
Launch timing and the pen itself
Onswik will come in a KwikPen, which the release says will be available in the United States “in the coming months.” It is not on pharmacy shelves yet. Two concentrations are planned, 500 units per milliliter (1,500 units total) and 1,000 units per milliliter (3,000 units total), each in a 3 milliliter single-patient-use pen. The release gives no price, and coverage terms were not announced. Lilly also points prescribers and patients to the full Prescribing Information, which governs the details of use, and lists a drug information line, 1-800-545-5979, for questions. Until the pens reach pharmacies, adults on daily basal insulin have no weekly option from this approval to switch to, and any change of regimen would be a decision for a prescriber.
Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health, framed the approval in terms of the company’s history. “For over a century, Lilly has been developing insulins that transformed diabetes care for millions of people worldwide,” he said, adding that “Onswik offers a new once-weekly basal insulin option for patients.” The full text appears in the wire version of the announcement.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Two passengers died at an Ohio toll plaza, and the NTSB now wants the cash lanes shut
- Long use of a common prostate pill is tied to a higher chance of glaucoma
- Ford is recalling 223,472 F-150 pickups because the fuel tank can leak or detach
- Hybrids have 15% fewer problems than gas cars, while EVs and plug-in hybrids have about 80% more, Consumer Reports finds
